HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by FAJARDO, T. T. Articles by GELBER, R. H. Search for Related Content PubMed PubMed Citation Articles by FAJARDO, T. T. Articles by GELBER, R. H. Related Collections Leprosy

A CLINICAL TRIAL OF ETHIONAMIDE AND PROTHIONAMIDE FOR TREATMENT OF LEPROMATOUS LEPROSY

In 1982–1984 we conducted a six-month clinical trial in 50 previously untreated lepromatous leprosy patients randomly assigned to directly observed monotherapy with one of two thioamides, ethionamide or prothionamide, each given six times a week at doses of either 250 mg or 500 mg. The findings of this study have only recently been analyzed, and the potential for the use of these thioamides in leprosy patients placed in perspective. However, because of the small number of patients included in this study, the results must be interpreted with some caution. Clinical improvement was noted in 74% of the patients treated with ethionamide and in 83% of those treated with prothionamide. Therapy was well tolerated and drug-related hepatotoxicity did not require discontinuation of therapy. The 500-mg dose of both ethionamide and prothionamide resulted in loss in Mycobacterium leprae viability more rapidly than did the 250-mg dose, and prothionamide at both dose levels was superior to the equivalent dose of ethionamide. Overall killing of M. leprae in this study was found to be similar to that obtained previously with dapsone and clofazimine, but less than was obtained with rifampin, minocycline, clarithromycin, pefloxacin, and ofloxacin.

Received January 26, 2005. Accepted for publication October 24, 2005.

Acknowledgments: We thank Judy Maseli (School of Medicine, University of California, San Francisco) for statistical consultations.

Financial support: This study was supported by the United Nations Development Program/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases.

^* Address correspondence to Robert H. Gelber, 220 Scenic Avenue, San Anselmo, CA 94960. E-mail: ikgelber{at}hotmail.com

Authors’ address: Tranquilino T. Fajardo, Ricardo S. Guinto, Roland V. Cellona, Rodolfo M. Abalos, and Eduardo C. Dela Cruz, Leonard Wood Memorial Center for Leprosy Research, Cebu City, Philippines, Telephone and Fax: 63-32-345-2751, E-mails: lwmrectr{at}cvis.net.ph, csc-epi{at}cvis.net.ph, and lwmrectr{at}cvis.net.ph. Robert H. Gelber, 220 Scenic Avenue, San Anselmo, CA 94960, Telephone: 415-154-8765, Fax: 415-454-8197, E-mail: ikgelber{at}hotmail.com.

This article has been cited by other articles:

				F. Wang, R. Langley, G. Gulten, L. G. Dover, G. S. Besra, W. R. Jacobs Jr., and J. C. Sacchettini Mechanism of thioamide drug action against tuberculosis and leprosy J. Exp. Med., January 22, 2007; 204(1): 73 - 78. [Abstract] [Full Text] [PDF]